-
Company Profile
![]()
ImmunityBio Inc – Company Profile
ImmunityBio Inc (ImmunityBio), formerly NantKwest Inc, a clinical-stage biotechnology company is developing therapies and vaccines that complement, harness and amplify the immune system to defeat cancers and infectious diseases. The company product pipeline includes n-803 + bcg for bladder cancer, anktiva + pd-l1 t-hank for lung cancer, anktiva + aldox +pd-l1 t-hank for pancreatic cancer, her2 t-hank for glioblastoma and anktiva + m-cenk for advanced solid tumor. ImmunityBio Anktiva, a lead candidate Anktiva are a novel class of biopharmaceuticals that...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – HRS-9531 in Obesity
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HRS-9531 in Obesity Drug Details: HRS-9531 is under development for the treatment of type 2...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Danazol in Endometriosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Danazol in Endometriosis Drug Details:Danazol is under development for the treatment of endometriosis. The drug candidate...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ck1 Alpha Degrader in Hematological Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Ck1 Alpha Degrader in Hematological TumorDrug Details:CK1 alpha degrader is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CB06-036 in Hepatitis B
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CB06-036 in Hepatitis B Drug Details: CB06-036 is under development for the treatment of hepatitis...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Batiraxcept in Uterine Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Batiraxcept in Uterine Cancer Drug Details: AVB-500 is under development for the treatment of acute...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TmPSMA 01 CAR-T in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TmPSMA 01 CAR-T in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details: TmPSMA 01 CAR-T...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Divarasib in Anal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Divarasib in Anal CancerDrug Details:Divarasib (GDC-6036 (RG6330)) is under development for the treatment of metastatic or...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BMS-986315 in Non-Small Cell Lung Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986315 in Non-Small Cell Lung Cancer Drug Details: BMS-986315 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Goserelin LA in Metastatic Prostate Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Goserelin LA in Metastatic Prostate Cancer Drug Details: Goserelin acetate (Goserelin Acetate) is a luteinising...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Daridorexant Hydrochloride in Obstructive Sleep Apnea
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Daridorexant Hydrochloride in Obstructive Sleep Apnea Drug Details:Daridorexant Hydrochloride (Quviviq) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MK-2118 in Cutaneous T-Cell Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MK-2118 in Cutaneous T-Cell Lymphoma Drug Details:MK-2118 is under development for the treatment of solid tumor...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Axitinib Sr in Wet (Neovascular / Exudative) Macular Degeneration
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Axitinib SR in Wet (Neovascular / Exudative) Macular Degeneration Drug Details:Axitinib (OTX-TKI) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GS-4182 in Human Immunodeficiency Virus (HIV) Infections (AIDS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.GS-4182 in Human Immunodeficiency Virus (HIV) Infections (AIDS)Drug Details:GS-4182 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GS-1720 in Human Immunodeficiency Virus (HIV) Infections (AIDS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.GS-1720 in Human Immunodeficiency Virus (HIV) Infections (AIDS)Drug Details:GS-1720 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Kid EDV in Pediatric Diffuse Intrinsic Pontine Glioma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Kid EDV in Pediatric Diffuse Intrinsic Pontine GliomaDrug Details:Kid EDV is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – AR-1001 in Alzheimer’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.AR-1001 in Alzheimer's Disease Drug Details: AR-1001 is under development for the treatment of Alzheimer's disease,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Designer Edv in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Designer Edv in Solid Tumor Drug Details: Designer EDV is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – M-ceNK in Non-Small Cell Lung Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. M-ceNK in Non-Small Cell Lung Cancer Drug Details: Cellular Immunotherapy is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – M-ceNK in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. M-ceNK in Solid Tumor Drug Details: Cellular Immunotherapy is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.